Maintrac® Companion Diagnostics
Maintrac Companion Diagnostics features world-class biomarker analysis. Information on the genetic activity of a person's cancer assists practitioners in gaining an understanding of the unique behaviour of a person's cancer cells. The biomarkers that are available for testing include: Estrogen Receptor, HER2/neu, Androgen Receptor, VEGF Receptor, EGF Receptor, ki-67, PLAP and BRaf mutations. This test can only be requested addition to the CTC-count test. Other biomarkers may be available upon request. The best way to monitor cancer activity and long-term effectiveness of treatment is via a single CTC Count test every 3-6 months. Patient information hand-outs or your clinic are available upon request by phoning 1300 282 482.
Medical director Dr. Joachim Fluhrer is available for expert consultation with medical and healthcare practitioners to discuss test selection and result interpretation.
Breast cancer: ER, PR, HER2-neu amplification
Prostate cancer: PSA, PSMA, AR, B7-H3
Lung: EGFR amplification
Ovarian: ER, PR
Melanonma: Melan A
Glioblastoma: PLAP, EGFR
Unknown origin: ACUP
This test can only be ordered in addition to a CTC Count Test, which is $630 in Australia and $715 in New Zealand.
ER, AR, PR, Ki-67, PLAPR, PD-L1, TUNEL, PSA, PSMA, B7-H3: $420
HER2/neu, EGFR, VEGFR, IGF1R, P53, c-Kit, Tissue Factor, Thomsen-Friedenreich Antigen, Antibodies against tumour cells: $490
Other biomarkers may be available – please contact Genostics to discuss price and availability.
Prices are in AUD and subject to change without notice
ORDER A TEST
Complete instructions for ordering a test, blood sample collection and dispatch can be found here
Tests can only be ordered by registered, certified Healthcare Practitioners.
To order, please download and complete a test request, and send it to Genostics via email (email@example.com) or fax (+61 2 8088 7097)
Companion Diagnostics - Patient Information
Poster: Somatic mutations of the EGFR, KRAS and BRAF genes: homogeneitiy in single cells from cell lines and heterogeneity in Circulating Epithelial Tumor Cells (CETCs) as determined using cobas® z480 analyzer (2014) ...View this poster This poster was awarded 'Best Poster' at the Clinical Oncology Society of Australia annual conference in Melbourne, 2014
Publication: Behaviour of Circulating Epithelial Tumor Cells (CETCs) and FISH (Fluorescence in situ hybridisation) of Epidermal Growth Factor Receptor (EGFR -gene amplification in lung cancer patients during the course of therapy ...Read this publication
Publication: Efficacy of control of therapy using Circulating Epithelial Tumor Cells (CETCs) as "Liquid Biopsy": trastuzumab in HER2/neu-positive breast carcinoma (2011) ...Read this publication
Publication: Insulin-like Growth Factor Receptor I (IGR-IR) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) are expressed on the Circulating Epithelial Tumor Cells of breast cancer patients ...Read this publication
Publication: An increase in cell number at the completion of therapy may develop as an indicator of early relapse (2008) ...Read this publication